Movement Alert｜Novo Nordisk Rises 3.24% in Regular Trading, CEO Announces Plan to Submit Oral Wegovy for China Approval

Market Focus06-17 21:38

On June 17, Novo Nordisk rose 3.24% in regular trading, trading at $44.905/share, with turnover of $68.62 million. The stock gained momentum following multiple positive catalysts centered on the company's oral weight-loss drug strategy.

Novo Nordisk's global CEO Mike Doustdar announced that the company plans to submit clinical data for oral Wegovy to Chinese regulators within the coming months to seek marketing approval. China represents Novo Nordisk's second-largest market globally after the United States. Doustdar also indicated that the company's BD transactions in China will increase, noting ongoing discussions with multiple Chinese companies. Additionally, oral Wegovy recently received approval from UK regulators, making it the first European market to clear the drug. Clinical trial data showed patients achieved average weight loss of 13.6% after 64 weeks. The CEO further clarified that semaglutide's regulatory data protection in China extends through Q2 2027, delaying generic competition.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196126511?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196126511","market":"us","top_or_hot":-1,"title":"Movement Alert｜Novo Nordisk Rises 3.24% in Regular Trading, CEO Announces Plan to Submit Oral Wegovy for China Approval","media":"Market Focus","content":"<p><p>On June 17, Novo Nordisk rose 3.24% in regular trading, trading at $44.905/share, with turnover of $68.62 million. The stock gained momentum following multiple positive catalysts centered on the company's oral weight-loss drug strategy.</p><p>Novo Nordisk's global CEO Mike Doustdar announced that the company plans to submit clinical data for oral Wegovy to Chinese regulators within the coming months to seek marketing approval. China represents Novo Nordisk's second-largest market globally after the United States. Doustdar also indicated that the company's BD transactions in China will increase, noting ongoing discussions with multiple Chinese companies. Additionally, oral Wegovy recently received approval from UK regulators, making it the first European market to clear the drug. Clinical trial data showed patients achieved average weight loss of 13.6% after 64 weeks. The CEO further clarified that semaglutide's regulatory data protection in China extends through Q2 2027, delaying generic competition.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Novo Nordisk Rises 3.24% in Regular Trading, CEO Announces Plan to Submit Oral Wegovy for China Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Novo Nordisk Rises 3.24% in Regular Trading, CEO Announces Plan to Submit Oral Wegovy for China Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-17 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 17, Novo Nordisk rose 3.24% in regular trading, trading at $44.905/share, with turnover of $68.62 million. The stock gained momentum following multiple positive catalysts centered on the company's oral weight-loss drug strategy.</p><p>Novo Nordisk's global CEO Mike Doustdar announced that the company plans to submit clinical data for oral Wegovy to Chinese regulators within the coming months to seek marketing approval. China represents Novo Nordisk's second-largest market globally after the United States. Doustdar also indicated that the company's BD transactions in China will increase, noting ongoing discussions with multiple Chinese companies. Additionally, oral Wegovy recently received approval from UK regulators, making it the first European market to clear the drug. Clinical trial data showed patients achieved average weight loss of 13.6% after 64 weeks. The CEO further clarified that semaglutide's regulatory data protection in China extends through Q2 2027, delaying generic competition.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1196126511","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196126511","pubTimestamp":1781703533,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 17, Novo Nordisk rose 3.24% in regular trading, trading at $44.905/share, with turnover of $68.62 million. The stock gained momentum following multiple positive catalysts centered on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"动静提示|诺和诺德常规交易涨3.24%CEO宣布拟将口服Wegovy提交中国审批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"On June 17, Novo Nordisk rose 3.24% in regular trading, trading at $44.905/share, with turnover of $68.62 million. The stock gained momentum following multiple positive catalysts centered on the company's oral weight-loss drug strategy.Novo Nordisk's global CEO Mike Doustdar announced that the company plans to submit clinical data for oral Wegovy to Chinese regulators within the coming months to seek marketing approval. China represents Novo Nordisk's second-largest market globally after the United States. Doustdar also indicated that the company's BD transactions in China will increase, noting ongoing discussions with multiple Chinese companies. Additionally, oral Wegovy recently received approval from UK regulators, making it the first European market to clear the drug. Clinical trial data showed patients achieved average weight loss of 13.6% after 64 weeks. The CEO further clarified that semaglutide's regulatory data protection in China extends through Q2 2027, delaying generic competition.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196126511","isCrawlerRequest":true}